Saturday, 23rd June 2018

Virology and Microbiology

  Human immunodeficiency virus reverse transcriptase and antiretroviral therapy

 

 

 2018 01 10 Grupo Luis Menéndez 03 400px

 


Luis Menéndez-Arias

 

 

BSciStaff

 

BPublications

 

 

Research summary

Infections caused by human immunodeficiency viruses type 1 and type 2 (HIV-1 and HIV-2, respectively) constitute a major burden to human health worldwide. Despite significant advances in antiretroviral therapy HIV still causes 1.6 million deaths each year. The HIV genome is composed of two copies of single-stranded RNA. The viral reverse transcriptase (RT) is responsible for the replication of the HIV genome. RT inhibitors constitute the backbone of the most popular and effective therapies.

For years, our efforts have been directed towards achieving two major goals: (1) the elucidation of molecular mechanisms involved in RT inhibitor resistance; and (2) understanding the role of different amino acids in the nucleotide specificity of HIV-1 and HIV-2 RTs, as well as in their fidelity of DNA synthesis. We have engineered HIV-1 RT variants with increased thermal stability and high fidelity that are currently marketed as biotechnological tools for many applications, covering basic and translational research. Future challenges involve the development of RTs with high nucleic acid binding affinity suitable for RNA amplification from single cells.

HIV-2 shows natural resistance to nonnucleoside RT inhibitors (NNRTIs) and several protease inhibitors. Nucleoside RT inhibitors (NRTIs) constitute the backbone of therapies against HIV. However, HIV-1 and HIV-2 show different mutational pathways of NRTI resistance. We are currently trying to identify the molecular determinants that lead to the development of different sets of NRTI resistance-associated mutations in both enzymes.

On the other hand, prevalence of drug-resistant HIV strains is increasing in less developed countries. Therefore, we anticipate an increasing interest in unexploited targets of antiretroviral intervention. In this context, RNase H activity and inhibition, as well as host factors that could eventually block HIV-1 replication are also important topics of research in our laboratory.

Imag01 300px

         

 . ................

Fig2 300px

 

 

Comparison of the structural models of wild-type and mutant HIV-1 RTs D67N/K70R and D67N/K70R/K73M, complexed with double-stranded DNA and an incoming dNTP. View of the β3-β4 hairpin loop, the incoming dNTP and the two Mg2+ ions, highlighting the effects of Met-73 on the interaction of Arg-70 with the dNTP. For details see Álvarez et al. (2017) J. Biol. Chem., in press.         RT-PCR assays showing the effect of the temperature on the cDNA synthesis catalyzed by engineered recombinant HIV-1 group O RT variants (Matamoros et al. 2013; Biochemistry 52, 9318).

 


 

Relevant publications:

  • Menéndez-Arias, L. (2013) Molecular basis of human immunodeficiency virus type 1 drug resistance: Overview and recent developments. Antiviral Res. 98, 93-120; doi: 10.1016/j.antiviral.2013.01.007.
  • Álvarez, M., Barrioluengo, V., Afonso-Lehmann, R., Menéndez-Arias, L. (2013) Altered error specificity of RNase H-deficient HIV-1 reverse transcriptases during DNA-dependent DNA synthesis. Nucleic Acids Res. 41, 4601-4612.  
  • Betancor, G., Álvarez, M., Marcelli, B., Andrés, C., Martínez, M.A., Menéndez-Arias, L. (2015) Effects of HIV-1 reverse transcriptase connection subdomain mutations on polypurine tract removal and initiation of (+)-strand DNA synthesis. Nucleic Acids Res. 43, 2259-2270.   
  • Álvarez, M., Sebastián-Martín, A., García-Marquina, G., Menéndez-Arias, L. (2017) Fidelity of classwide-resistant HIV-2 reverse transcriptase and differential contribution of K65R to the accuracy of HIV-1 and HIV-2 reverse transcriptases. Scientific Reports 7, 44384; doi: 10.1038/srep44834.  
  • Álvarez, M., Nevot, M., Mendieta, J., Martínez, M.A., Menéndez-Arias, L. (2017) Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway. J. Biol. Chem., published on-line, Dec 22nd, 2017; doi:10.1074/jbc.RA117.000177.